Helen J Gogas

Summary

Affiliation: University of Athens
Country: Greece

Publications

  1. ncbi Randomized phase III study of 1 month versus 1 year of adjuvant high-dose interferon alfa-2b in patients with resected high-risk melanoma
    Dimitrios Pectasides
    Second Department of Internal Medicine Propaedeutic, Oncology Section, University General Hospital Attikon, Athens, Greece
    J Clin Oncol 27:939-44. 2009
  2. ncbi Evaluation of six CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferon therapy in the He13A/98 multicenter trial
    Helen Gogas
    First Department of Medicine, University of Athens, Medical School, Athens, Greece
    J Transl Med 8:108. 2010
  3. ncbi Future perspectives in melanoma research. Meeting report from the "Melanoma research: a bridge from Naples to the World. Napoli, December 5th-6th 2011"
    Paolo A Ascierto
    Department of Melanoma, Sarcoma, and Head and Neck Disease, Istituto Nazionale Tumori Fondazione Pascale, Naples, Italy
    J Transl Med 10:83. 2012
  4. ncbi HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy
    George Fountzilas
    Department of Medical Oncology, Papageorgiou Hospital, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece
    J Transl Med 10:10. 2012
  5. ncbi Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III Trial
    Helen Gogas
    1st Department of Medicine, Laiko General Hospital, University of Athens, Medical School, PO Box 14120, Athens 11510, Greece
    Breast Cancer Res Treat 132:609-19. 2012
  6. ncbi Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial
    Christos Markopoulos
    Hellenic Society of Breast Surgeons, 6 Eslin Street, Athens, Greece
    Breast Cancer Res 12:R24. 2010
  7. ncbi Extended adjuvant hormonal therapy with exemestane has no detrimental effect on the lipid profile of postmenopausal breast cancer patients: final results of the ATENA lipid substudy
    Christos Markopoulos
    Hellenic Society of Breast Surgeons, Athens, Greece
    Breast Cancer Res 11:R35. 2009
  8. ncbi Biomarkers in melanoma
    H Gogas
    First Department of Medicine, Medical School, University of Athens, Greece
    Ann Oncol 20:vi8-13. 2009
  9. ncbi Prognostic significance of autoimmunity during treatment of melanoma with interferon
    Helen Gogas
    First Department of Medicine, Laiko Hospital, Athens, Greece
    N Engl J Med 354:709-18. 2006
  10. ncbi Temozolomide in combination with celecoxib in patients with advanced melanoma. A phase II study of the Hellenic Cooperative Oncology Group
    H Gogas
    First Department of Medicine, University of Athens, Medical School, Athens, Greece
    Ann Oncol 17:1835-41. 2006

Detail Information

Publications42

  1. ncbi Randomized phase III study of 1 month versus 1 year of adjuvant high-dose interferon alfa-2b in patients with resected high-risk melanoma
    Dimitrios Pectasides
    Second Department of Internal Medicine Propaedeutic, Oncology Section, University General Hospital Attikon, Athens, Greece
    J Clin Oncol 27:939-44. 2009
    ....
  2. ncbi Evaluation of six CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferon therapy in the He13A/98 multicenter trial
    Helen Gogas
    First Department of Medicine, University of Athens, Medical School, Athens, Greece
    J Transl Med 8:108. 2010
    ..Specific CTLA-4 polymorphisms have previously shown an association with response to CTLA-4 blockade in patients with metastatic melanoma and the development of autoimmunity...
  3. ncbi Future perspectives in melanoma research. Meeting report from the "Melanoma research: a bridge from Naples to the World. Napoli, December 5th-6th 2011"
    Paolo A Ascierto
    Department of Melanoma, Sarcoma, and Head and Neck Disease, Istituto Nazionale Tumori Fondazione Pascale, Naples, Italy
    J Transl Med 10:83. 2012
    ....
  4. ncbi HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy
    George Fountzilas
    Department of Medical Oncology, Papageorgiou Hospital, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece
    J Transl Med 10:10. 2012
    ..The aim of this study was to comprehensively evaluate the prognostic/predictive significance of the above parameters in early, high-risk breast cancer patients treated with epirubicin-based, dose-dense sequential adjuvant chemotherapy...
  5. ncbi Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III Trial
    Helen Gogas
    1st Department of Medicine, Laiko General Hospital, University of Athens, Medical School, PO Box 14120, Athens 11510, Greece
    Breast Cancer Res Treat 132:609-19. 2012
    ..No DFS or OS benefit from the dose-dense sequential epirubicin and paclitaxel was detected when compared to the concurrent administration of the same drugs. No additional safety issues were raised with long-term follow-up...
  6. ncbi Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial
    Christos Markopoulos
    Hellenic Society of Breast Surgeons, 6 Eslin Street, Athens, Greece
    Breast Cancer Res 12:R24. 2010
    ....
  7. ncbi Extended adjuvant hormonal therapy with exemestane has no detrimental effect on the lipid profile of postmenopausal breast cancer patients: final results of the ATENA lipid substudy
    Christos Markopoulos
    Hellenic Society of Breast Surgeons, Athens, Greece
    Breast Cancer Res 11:R35. 2009
    ....
  8. ncbi Biomarkers in melanoma
    H Gogas
    First Department of Medicine, Medical School, University of Athens, Greece
    Ann Oncol 20:vi8-13. 2009
    ..A more accurate, therapeutically predictive classification of human melanomas and selection of patient populations that would profit from therapeutic interventions are among the major challenges expected to be addressed in the future...
  9. ncbi Prognostic significance of autoimmunity during treatment of melanoma with interferon
    Helen Gogas
    First Department of Medicine, Laiko Hospital, Athens, Greece
    N Engl J Med 354:709-18. 2006
    ..We assessed the prognostic significance of autoimmunity in patients with stage IIB, IIC, or III melanoma who were treated with high-dose adjuvant interferon alfa-2b...
  10. ncbi Temozolomide in combination with celecoxib in patients with advanced melanoma. A phase II study of the Hellenic Cooperative Oncology Group
    H Gogas
    First Department of Medicine, University of Athens, Medical School, Athens, Greece
    Ann Oncol 17:1835-41. 2006
    ..We designed a phase II study to assess the efficacy and toxicity of the combination of TMZ and celecoxib (a COX-2 inhibitor) in patients with advanced melanoma...
  11. ncbi Chemotherapy for metastatic melanoma: time for a change?
    Helen J Gogas
    First Department of Internal Medicine, University of Athens, Athens, Greece
    Cancer 109:455-64. 2007
    ..They discuss roles of single-agent chemotherapy, combination chemotherapy, combinations of chemotherapy with immunomodulatory or hormone agents, biochemotherapy, and combination chemotherapy with targeted therapies...
  12. ncbi Correlation of molecular human leukocyte antigen typing and outcome in high-risk melanoma patients receiving adjuvant interferon
    Helen Gogas
    First Department of Medicine, University of Athens, Medical School, Athens, Greece
    Cancer 116:4326-33. 2010
    ..Specific human leukocyte antigen (HLA) class I and II antigens have previously shown an association with response to therapy or overall survival of patients with metastatic melanoma...
  13. ncbi Predictors of response to interferon therapy
    Helen Gogas
    First Department of Internal Medicine, University of Athens, Greece
    Curr Opin Oncol 21:138-43. 2009
    ....
  14. ncbi The role of taxanes in the treatment of metastatic melanoma
    Helen Gogas
    First Department of Medicine, National and Kapodistrian University of Athens, Laiko General Hospital, Athens 11 527, Greece
    Melanoma Res 14:415-20. 2004
    ..Taxanes, both as single agents and in combinations, may be a treatment option for some patients with metastatic melanoma, especially in the second-line setting...
  15. ncbi Should women be advised to take prophylactic endocrine treatment outside of a clinical trial setting?
    H Gogas
    First Department of Internal Medicine, Athens Medical School, National and Kapodistrian University of Athens, Athens, Greece
    Ann Oncol 16:1861-6. 2005
    ..High-risk women should not be advised to take anti-estrogens outside of a clinical trial setting...
  16. ncbi Vinorelbine in combination with interleukin-2 as second-line treatment in patients with metastatic melanoma. A phase II study of the Hellenic Cooperative Oncology Group
    Helen Gogas
    First Department of Medicine, University of Athens, Athens, Greece
    Cancer Invest 22:832-9. 2004
    ..To evaluate the efficacy and toxicity of the combination of vinorelbine and interleukin (IL)-2 in patients with metastatic melanoma as second-line chemotherapy...
  17. ncbi Prognostic significance of the sequential detection of circulating melanoma cells by RT-PCR in high-risk melanoma patients receiving adjuvant interferon
    H Gogas
    Research Laboratory of 1st Department of Medicine, University of Athens Aghiou Thoma 17, Goudi, Athens 11 527, Greece
    Br J Cancer 87:181-6. 2002
    ..Tyrosinase mRNA amplification by reverse-transcriptase-polymerase chain reaction may be a useful tool for monitoring the efficacy of adjuvant treatment in stage IIB and III melanoma patients...
  18. ncbi Neoadjuvant chemotherapy with a combination of pegylated liposomal doxorubicin (Caelyx) and paclitaxel in locally advanced breast cancer: a phase II study by the Hellenic Cooperative Oncology Group
    H Gogas
    First Department of Medicine, Laiko Hospital, University of Athens, Greece
    Ann Oncol 13:1737-42. 2002
    ..To determine the activity and safety of the combination of paclitaxel and pegylated liposomal doxorubicin (Caelyx) in patients with locally advanced breast cancer...
  19. ncbi The role of taxanes as a component of neoadjuvant chemotherapy for breast cancer
    H Gogas
    First Department of Medicine, Laiko Hospital, University of Athens, Athens, Grece
    Ann Oncol 14:667-74. 2003
  20. ncbi Tolerability of adjuvant high-dose interferon alfa-2b: 1 month versus 1 year--a Hellenic Cooperative Oncology Group study
    Helen Gogas
    University of Athens, Laikon Hospital, 11 527 Athens, Greece
    Anticancer Res 24:1947-52. 2004
    ..It has been suggested that the 1-month intravenous (i.v.) induction regimen may be sufficient to reduce the risk of relapse and death...
  21. ncbi Paclitaxel and carboplatin as neoadjuvant chemotherapy in patients with locally advanced breast cancer: A phase II Trial of the Hellenic Cooperative Oncology Group
    Helen Gogas
    First Department of Medicine, Laiko General Hospital, Athens, Greece
    Clin Breast Cancer 10:230-7. 2010
    ..This phase II study sought to evaluate the efficacy of the paclitaxel-carboplatin combination as neoadjuvant chemotherapy in patients with locally advanced breast cancer (LABC)...
  22. ncbi Docetaxel and epirubicin supported by granulocyte colony-stimulating factor first-line in advanced breast cancer
    Aristides Polyzos
    Medical Oncology Unit, Laikon General Hospital, Athens University School of Medicine, 17 Agiou Thoma Street, Goudi, GR 11527, Athens, Greece
    Anticancer Res 23:2917-23. 2003
    ..Although myelosuppression remains the major toxicity, prophylactic GCSF administration was associated with a small percentage of neutropenic fever...
  23. ncbi Subsets of patients with advanced gastric cancer responding to second-line chemotherapy with docetaxel-cisplatin
    Aristides Polyzos
    Medical Oncology Unit, Laikon General Hospital, Athens University School of Medicine, Athens, Greece
    Anticancer Res 26:3749-53. 2006
    ..According to our results, it seems that patients, whose tumors were not exposed to cisplatin during first-line chemotherapy, were more likely to respond to this regimen...
  24. ncbi Melanocortin receptor-1 gene polymorphisms and the risk of cutaneous melanoma in a low-risk southern European population
    Alexander J Stratigos
    Department of Dermatology, University of Athens Medical School, Andreas Sygros Hospital, Athens, Greece
    J Invest Dermatol 126:1842-9. 2006
    ..In conclusion, MC1R polymorphisms are a predisposing factor of melanoma in a southern European population with a relatively low incidence of the disease...
  25. ncbi Paclitaxel-ifosfamide-cisplatin as salvage chemotherapy in ovarian cancer patients pretreated with platinum compounds and paclitaxel
    Aristides Polyzos
    Medical Oncology Unit, Laiko General Hospital, Athens University School of Medicine, Athens, Greece
    Anticancer Res 27:1645-51. 2007
    ..Given the in vitro and in vivo synergism between these three agents, it was believed that using a three drug combination would overcome tumor resistance to cisplatin...
  26. ncbi Glycogen-rich clear cell carcinoma of the breast
    Christos Markopoulos
    Breast Unit, 2nd Propedeutic Department of Surgery, Athens University Medical School, Greece
    World J Surg Oncol 6:44. 2008
    ..Glycogen-rich carcinoma of the breast is a rare histological subtype of breast cancer, usually reported to have poor prognosis...
  27. ncbi Salvage chemotherapy with oxaliplatin and capecitabine for breast cancer patients pretreated with anthracyclines and taxanes
    Aristides Polyzos
    Department of Propaedeutic Medicine, Medical Oncology Unit, Laiko General Hospital, Athens University School of Medicine, Athens, Greece
    Anticancer Res 29:2851-6. 2009
    ..The present regimen was well tolerated with a rather moderate effectiveness but very significant for this group of patients. Further studies where the combination could be compared with single agent capecitabine are warranted...
  28. ncbi Gemcitabine plus pegylated liposomal doxorubicin in patients with advanced epithelial ovarian cancer resistant/refractory to platinum and/or taxanes. A HeCOG phase II study
    Dimosthenis V Skarlos
    Second Department of Medical Oncology, Henry Dunant Hospital, Athens, Greece
    Anticancer Res 25:3103-8. 2005
    ....
  29. ncbi Lymphocyte subpopulations and interleukin levels in high-risk melanoma patients treated with high-dose interferon A-2B
    Helen Gogas
    1st Department of Internal Medicine, Athens University, Laiko Hospital, Athens, Greece
    Am J Clin Oncol 25:591-6. 2002
    ..Defects in cellular and humoral immunity are suggested by the low IL-2 and high IL-5 levels, measured in patients with melanoma as compared with healthy controls...
  30. ncbi Risk associations of melanoma in a Southern European population: results of a case/control study
    Vasiliki A Nikolaou
    Department of Dermatology, University of Athens, Andreas Sygros Hospital, 5 Dragoumi Street, Athens, 10671, Greece
    Cancer Causes Control 19:671-9. 2008
    ..We investigated the association of melanoma with phenotypic and solar indices in this darker skin population residing in an environment of high ambient ultraviolet radiation...
  31. ncbi Molecular markers detecting circulating melanoma cells by reverse transcription polymerase chain reaction: methodological pitfalls and clinical relevance
    Adrianos Nezos
    Department of Experimental Physiology, National and Kapodistrian University of Athens, Athens, Greece
    Clin Chem Lab Med 47:1-11. 2009
    ..Finally, we comment on the contradictory data of CMC detection studies in the literature and we propose possible solutions which may contribute to the clinical significance of CMC detection in patient management...
  32. ncbi Cisplatin-Ifosfamide-gemcitabine as salvage chemotherapy in ovarian cancer patients pretreated with platinum compounds and Paclitaxel
    Aristides Polyzos
    Medical Oncology Unit, Laiko General Hospital, Athens University School of Medicine, Athens, Greece
    Anticancer Res 29:2681-6. 2009
    ..Given the in vitro and in vivo synergism between the three agents, it was believed that using a three-drug combination would overcome tumor resistance to cisplatin...
  33. ncbi Metastatic breast cancer with liver metastases: a registry analysis of clinicopathologic, management and outcome characteristics of 500 women
    George Pentheroudakis
    Hellenic Cooperative Oncology Group HeCoG, Athens, Greece
    Breast Cancer Res Treat 97:237-44. 2006
    ..We sought to examine the epidemiology, clinical course, outcome and prognostic factors of this cohort with the hope to identify changing patterns, facilitate cost-effective follow-up and rationalize therapy of these patients...
  34. ncbi Trastuzumab combined with pegylated liposomal doxorubicin in patients with metastatic breast cancer. phase II Study of the Hellenic Cooperative Oncology Group (HeCOG) with biomarker evaluation
    Christos Christodoulou
    Second Department of Medical Oncology, Henry Dunant Hospital, Athens, Greece
    Oncology 76:275-85. 2009
    ..Pegylated liposomal doxorubicin (PLD) is the least cardiotoxic among the anthracyclines. We performed a phase II study of trastuzumab and PLD with biomarker evaluation...
  35. ncbi Obesity and risk of malignant melanoma: a meta-analysis of cohort and case-control studies
    Theodoros N Sergentanis
    Department of Hygiene, Epidemiology and Medical Statistics, Athens University Medical School, Athens, Greece
    Eur J Cancer 49:642-57. 2013
    ..Higher-order associations between BMI and melanoma risk should be addressed and examined by the future studies...
  36. ncbi Metastatic melanoma in the gallbladder: report of a case
    John Gogas
    Second Department of Propedeutic Surgery, Athens University School of Medicine, Laiko General Hospital, Ag. Thomas Str. 17, 115-27 Goudi, Athens, Greece
    Surg Today 33:135-7. 2003
    ..Surgical removal of a solitary metastatic focus remains the treatment of choice for isolated metastasis of a malignant melanoma; however, the effectiveness of complementary chemotherapy and immunotherapy is still being examined...
  37. ncbi Docetaxel and gemcitabine combination, as first-line treatment, in patients with extensive disease small-cell lung cancer. A phase II study of the Hellenic Cooperative Oncology Group
    Dimosthenis Vasilios Skarlos
    Henry Dynan Hospital, Athens, Greece
    Lung Cancer 41:107-11. 2003
    ..In conclusion, docetaxel-gemcitabine showed a modest response rate in chemotherapy-naive patients with ED SCLC...
  38. ncbi Survivin and glycodelin transcriptional activity in node-positive early breast cancer: mRNA expression of two key regulators of cell survival
    Lida Kostadima
    Hellenic Cooperative Oncology Group, Athens, Greece
    Breast Cancer Res Treat 100:161-7. 2006
    ..Further study is needed for illumination of their functional roles in tumorigenesis...
  39. ncbi Diagnosis and treatment of intracystic breast carcinomas
    Christos Markopoulos
    Second Department of Propedeutic Surgery, Athens University Medical School, Laiko General Hospital, Greece
    Am Surg 68:783-6. 2002
    ..Bloodstained aspirated cyst fluid should be sent for cytology and breast imaging should be carried out in all these cases. Residual mass after cyst aspiration is also an indication for open biopsy...
  40. ncbi Greek BRCA1 and BRCA2 mutation spectrum: two BRCA1 mutations account for half the carriers found among high-risk breast/ovarian cancer patients
    Irene Konstantopoulou
    Molecular Diagnostics Laboratory, I R RP, National Center for Scientific Research Demokritos, Athens, Greece
    Breast Cancer Res Treat 107:431-41. 2008
    ..The suggested protocol can impact on the clinical management of breast-ovarian cancer families on a national healthcare system level...
  41. ncbi Liposomal doxorubicin in conjunction with reirradiation and local hyperthermia treatment in recurrent breast cancer: a phase I/II trial
    Vassilios E Kouloulias
    Radiotherapy Department, Areteion University Hospital, Athens
    Clin Cancer Res 8:374-82. 2002
    ..Local HT had a significant effect on patients' response to the drug. The relationship between thermal dose and liposomal action requires further investigation...
  42. ncbi Next generation of immunotherapy for melanoma
    John M Kirkwood
    Hillman Cancer Center, Research Pavilion, Suite 1 32, 5117 Centre Ave, Pittsburgh, PA 15213 2584, USA
    J Clin Oncol 26:3445-55. 2008
    ..Immunotherapy has a long history with striking but limited success in patients with melanoma. To date, interleukin-2 and interferon-alfa2b are the only approved immunotherapeutic agents for melanoma in the United States...